{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T09:54:07Z","timestamp":1781690047953,"version":"3.54.5"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,7]],"date-time":"2020-07-07T00:00:00Z","timestamp":1594080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,7]],"date-time":"2020-07-07T00:00:00Z","timestamp":1594080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Women's Health"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>A wide range of drugs have been studied for first trimester medical abortion. Studies evaluating different regimens, including combination mifepristone and misoprostol and misoprostol alone regimens, show varying results related to safety, efficacy and other outcomes. Thus, the objectives of this systematic review were to compare the safety, effectiveness and acceptability of medical abortion and to compare medical with surgical methods of abortion \u226463\u2009days of gestation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Pubmed and EMBASE were systematically searched from database inception through January 2019 using a combination of MeSH, keywords and text words.<\/jats:p>\n                    <jats:p>Randomized controlled trials on induced abortion at \u226463\u2009days that compared different regimens of medical abortion using mifepristone and\/or misoprostol and trials that compared medical with surgical methods of abortion were included.<\/jats:p>\n                    <jats:p>We extracted data into a pre-designed form, calculated effect estimates, and performed meta-analyses where possible. The primary outcomes were ongoing pregnancy and successful abortion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty-three studies composed of 22,275 participants were included in this review. Combined regimens using mifepristone and misoprostol had lower rates of ongoing pregnancy, higher rates of successful abortion and satisfaction compared to misoprostol only regimens. In combined regimens, misoprostol 800\u2009\u03bcg was more effective than 400\u2009\u03bcg. There was no significant difference in dosing intervals between mifepristone and misoprostol and routes of misoprostol administration in combination or misoprostol alone regimens. The rate of serious adverse events was generally low.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this systematic review, we find that medical methods of abortion utilizing combination mifepristone and misoprostol or misoprostol alone are effective, safe and acceptable. More robust studies evaluating both the different combination and misoprostol alone regimens are needed to strengthen existing evidence as well as assess patient perspectives towards a particular regimen.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12905-020-01003-8","type":"journal-article","created":{"date-parts":[[2020,7,7]],"date-time":"2020-07-07T06:03:38Z","timestamp":1594101818000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Medical termination for pregnancy in early first trimester (\u2264 63 days) using combination of mifepristone and misoprostol or misoprostol alone: a systematic review"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2624-544X","authenticated-orcid":false,"given":"Ferid A.","family":"Abubeker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Lavelanet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria I.","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caron","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,7]]},"reference":[{"issue":"3","key":"1003_CR1","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/0010-7824(71)90030-8","volume":"3","author":"SMM Karim","year":"1971","unstructured":"Karim SMM. Once-a-month vaginal administration of prostaglandins E2 and F2\u03b1 for fertility control. Contraception. 1971;3(3):173\u201383.","journal-title":"Contraception"},{"issue":"716","key":"1003_CR2","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1136\/bmj.3.5716.196","volume":"3","author":"SMM Karim","year":"1970","unstructured":"Karim SMM. Use of prostaglandin E2 in the management of missed abortion, missed labour, and hydatidiform mole. Br Med J. 1970;3(716):196\u20137.","journal-title":"Br Med J"},{"key":"1003_CR3","doi-asserted-by":"crossref","unstructured":"Karim S, Rao B, Ratnam S, Prasad R, Wong Y, Ilancheran A. Termination of early pregnancy (menstrual induction) with 16-phenoxy-\u03c9-tetranor PGE2 methylsulfonylamide. Contraception 1977;16(4):377\u201381.","DOI":"10.1016\/0010-7824(77)90049-X"},{"issue":"1","key":"1003_CR4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0010-7824(99)00115-8","volume":"61","author":"JG Kahn","year":"2000","unstructured":"Kahn JG, Becker BJ, Maclsaa L, Amory JK, Neuhaus J, Olkin I, Creinin MD. The efficacy of medical abortion: a meta-analysis. Contraception. 2000;61(1):29\u201340.","journal-title":"Contraception"},{"key":"1003_CR5","doi-asserted-by":"publisher","unstructured":"Kulier R, Kapp N, G\u00fclmezoglu AM, Hofmeyr GJ, Cheng L, Campana A. Medical methods for first trimester abortion. Cochrane Database of Systematic Reviews 2011, Issue 11. Art. No.: CD002855. DOI: https:\/\/doi.org\/10.1002\/14651858.CD002855.pub4.","DOI":"10.1002\/14651858.CD002855.pub4"},{"issue":"2","key":"1003_CR6","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.ijgo.2012.03.039","volume":"118","author":"J Blum","year":"2012","unstructured":"Blum J, Raghavan S, Dabash R, Ngoc N, Chelli H, Hajri S, Conkling K, Winikoff B. Comparison of misoprostol-only and combined mifepristone-misoprostol regimens for home-based early medical abortion in Tunisia and Vietnam. Int J Gynaecol Obstet. 2012;118(2):166\u201371.","journal-title":"Int J Gynaecol Obstet"},{"issue":"4","key":"1003_CR7","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s00404-011-2110-8","volume":"285","author":"K Dahiya","year":"2012","unstructured":"Dahiya K, Ahuja K, Dhingra A, Duhan N, Nanda S. Efficacy and safety of mifepristone and buccal misoprostol versus buccal misoprostol alone for medical abortion. Arch Gynecol Obstet. 2012;285(4):1055\u20138.","journal-title":"Arch Gynecol Obstet"},{"issue":"5","key":"1003_CR8","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.contraception.2010.09.002","volume":"83","author":"NT Ngoc","year":"2011","unstructured":"Ngoc NT, Blum J, Raghavan S, Nga NT, Dabash R, Diop A, Winikoff B. Comparing two early medical abortion regimens: mifepristone+misoprostol vs. misoprostol alone. Contraception. 2011;83(5):410\u20137.","journal-title":"Contraception"},{"issue":"3","key":"1003_CR9","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.contraception.2011.12.012","volume":"86","author":"E Chong","year":"2012","unstructured":"Chong E, Tsereteli T, Nguyen NN, Winikoff B. A randomized controlled trial of different buccal misoprostol doses in mifepristone medical abortion. Contraception. 2012;86(3):251\u20136.","journal-title":"Contraception"},{"issue":"10","key":"1003_CR10","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1111\/j.1471-0528.2010.02636.x","volume":"117","author":"H von Hertzen","year":"2010","unstructured":"von Hertzen H, Huong NT, Piaggio G, Bayalag M, Cabezas E, Fang AH, Gemzell-Danielsson K, Hinh ND, Mittal S, Ng EH, Chaturachinda K, Pinter B, Puscasiu L, Savardekar L, Shenoy S, Khomassuridge A, Tuyet HT, Velasco A, Peregoudov A. Misoprostol dose and route after mifepristone for early medical abortion: a randomised controlled noninferiority trial. BJOG. 2010;117(10):1186\u201396.","journal-title":"BJOG"},{"key":"1003_CR11","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/j.1471-0528.2006.01179.x","volume":"114","author":"J Guest","year":"2007","unstructured":"Guest J, Dog PFW, Thomson MAR, Kosseim ML. Randomized controlled trial of the efficacy of same-day administration of mifepristone and misoprostol for termination of pregnancy with the standard 36 to 48 hour protocol. BJOG Int J Obstet Gynecol. 2007;114:207\u201315.","journal-title":"BJOG Int J Obstet Gynecol"},{"issue":"4","key":"1003_CR12","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1097\/01.AOG.0000258298.35143.d2","volume":"109","author":"MD Creinin","year":"2007","unstructured":"Creinin MD, Schreiber CA, Bednarek P, Lintu H, Wagner MS, Meyn LA. Mifepristone and misoprostol administered simultaneously versus 24 hours apart for abortion: a randomized controlled trial. Obstet Gynecol. 2007;109(4):885\u201394.","journal-title":"Obstet Gynecol"},{"issue":"12","key":"1003_CR13","doi-asserted-by":"publisher","first-page":"511","DOI":"10.4103\/0019-5359.109900","volume":"65","author":"ML Verma","year":"2011","unstructured":"Verma ML, Singh U, Singh N, Shankhwar P, Srivastava D. Efficacy of misoprostol administration 24 hours after mifepristone for termination of early pregnancy. Indian J Med Sci. 2011;65(12):511\u20137.","journal-title":"Indian J Med Sci"},{"issue":"2","key":"1003_CR14","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.contraception.2005.02.008","volume":"72","author":"K Blanchard","year":"2005","unstructured":"Blanchard K, Shochet T, Coyaji K, Thi Nhu Ngoc N, Winikoff B. Misoprostol alone for early abortion: an evaluation of seven potential regimens. Contraception. 2005;72(2):91\u20137.","journal-title":"Contraception"},{"key":"1003_CR15","unstructured":"Covidence systematic review software, Veritas Health Innovation, Melbourne, Australia. Available at www.covidence.org."},{"key":"1003_CR16","unstructured":"Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org."},{"key":"1003_CR17","unstructured":"World Bank Data Team. New country classifications by income level: 2018-2019. 2018. Available from: https:\/\/blogs.worldbank.org\/opendata\/newcountry-classifications-income-level-2018-2019. Accessed 28 Oct 2018."},{"issue":"4","key":"1003_CR18","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.contraception.2012.09.022","volume":"87","author":"J Chai","year":"2013","unstructured":"Chai J, Wong CY, Ho PC. A randomized clinical trial comparing the short-term side effects of sublingual and buccal routes of misoprostol administration for medical abortions up to 63 days' gestation. Contraception. 2013;87(4):480\u20135.","journal-title":"Contraception"},{"issue":"1","key":"1003_CR19","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/j.1447-0756.2008.00864.x","volume":"35","author":"R Chawdhary","year":"2009","unstructured":"Chawdhary R, Rana A, Pradhan N. Mifepristone plus vaginal misoprostol vs vaginal misoprostol alone for medical abortion in gestation 63 days or less in Nepalese women: a quasi-randomized controlled trial. J Obstet Gynaecol Res. 2009;35(1):78\u201385.","journal-title":"J Obstet Gynaecol Res"},{"issue":"3","key":"1003_CR20","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/j.1471-0528.2006.01208.x","volume":"114","author":"K Coyaji","year":"2007","unstructured":"Coyaji K, Krishna U, Ambardekar S, Bracken H, Raote V, Mandlekar A, Winikoff B. Are two doses of misoprostol after mifepristone for early abortion better than one? BJOG. 2007;114(3):271\u20138.","journal-title":"BJOG"},{"issue":"1","key":"1003_CR21","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s00404-010-1590-2","volume":"284","author":"K Dahiya","year":"2011","unstructured":"Dahiya K, Mann S, Nanda S. Randomized trial of oral versus sublingual misoprostol 24 h after mifepristone for medical abortion. Arch Gynecol Obstet. 2011;284(1):59\u201363.","journal-title":"Arch Gynecol Obstet"},{"issue":"9","key":"1003_CR22","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1111\/j.1471-0528.1994.tb11948.x","volume":"101","author":"H El-Refaey","year":"1994","unstructured":"El-Refaey H, Templeton A. Early abortion induction by a combination of mifepristone and oral misoprostol: a comparison between two dose regimens of misoprostol and their effect on blood pressure. Br J Obstet Gynaecol. 1994;101(9):792\u20136.","journal-title":"Br J Obstet Gynaecol"},{"issue":"15","key":"1003_CR23","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1056\/NEJM199504133321502","volume":"332","author":"H El-Refaey","year":"1995","unstructured":"El-Refaey H, Rajasekar D, Abdalla M, Calder L, Templeton A. Induction of abortion with mifepristone (RU 486) and oral or vaginal misoprostol. N Engl J Med. 1995;332(15):983\u20137.","journal-title":"N Engl J Med"},{"issue":"1","key":"1003_CR24","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ijgo.2009.11.008","volume":"109","author":"M Fekih","year":"2010","unstructured":"Fekih M, Fathallah K, Ben Regaya L, Bouguizane S, Chaieb A, Bibi M, Khairi H. Sublingual misoprostol for first trimester termination of pregnancy. Int J Gynaecol Obstet. 2010;109(1):67\u201370.","journal-title":"Int J Gynaecol Obstet"},{"issue":"6","key":"1003_CR25","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1007\/s00404-011-1881-2","volume":"283","author":"A Goel","year":"2011","unstructured":"Goel A, Mittal S, Taneja BK, Singal N, Attri S. Simultaneous administration of mifepristone and misoprostol for early termination of pregnancy: a randomized controlled trial. Arch Gynecol Obstet. 2011;283(6):1409\u201313.","journal-title":"Arch Gynecol Obstet"},{"issue":"8","key":"1003_CR26","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1111\/j.1471-0528.2005.00638.x","volume":"112","author":"H Hamoda","year":"2005","unstructured":"Hamoda H, Ashok PW, Flett GM, Templeton A. A randomised controlled trial of mifepristone in combination with misoprostol administered sublingually or vaginally for medical abortion up to 13 weeks of gestation. BJOG. 2005;112(8):1102\u20138.","journal-title":"BJOG"},{"issue":"6","key":"1003_CR27","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1093\/humrep\/17.6.1477","volume":"17","author":"JK Jain","year":"2002","unstructured":"Jain JK, Dutton C, Harwood B, Meckstroth KR, Mishell DR Jr. A prospective randomized, double-blinded, placebo-controlled trial comparing mifepristone and vaginal misoprostol to vaginal misoprostol alone for elective termination of early pregnancy. Hum Reprod (Oxford, Engl). 2002;17(6):1477\u201382.","journal-title":"Hum Reprod (Oxford, Engl)"},{"issue":"5","key":"1003_CR28","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.contraception.2005.05.017","volume":"72","author":"T Middleton","year":"2005","unstructured":"Middleton T, Schaff E, Fielding SL, Scahill M, Shannon C, Westheimer E, Wilkinson T, Winikoff B. Randomized trial of mifepristone and buccal or vaginal misoprostol for abortion through 56 days of last menstrual period. Contraception. 2005;72(5):328\u201332.","journal-title":"Contraception"},{"issue":"1","key":"1003_CR29","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.fertnstert.2007.11.028","volume":"91","author":"S Prasad","year":"2009","unstructured":"Prasad S, Kumar A, Divya A. Early termination of pregnancy by single-dose 800 \u03bcg misoprostol compared with surgical evacuation. Fertil Steril. 2009;91(1):28\u201331.","journal-title":"Fertil Steril"},{"key":"1003_CR30","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.contraception.2008.09.001","volume":"79","author":"S Raghavana","year":"2009","unstructured":"Raghavana S, Comendant R, Digol I, Ungureanu S, Friptu V, Bracken H, Winikoff B. Two-pill regimens of misoprostol after mifepristone medical abortion through 63 days' gestational age: a randomized controlled trial of sublingual and oral misoprostol. Contraception. 2009;79:84\u201390.","journal-title":"Contraception."},{"issue":"6","key":"1003_CR31","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.contraception.2010.05.013","volume":"82","author":"S Raghavan","year":"2010","unstructured":"Raghavan S, Comendant R, Digol I, Ungureanu S, Dondiuc I, Turcanu S, Winikoff B. Comparison of 400 mcg buccal and 400 mcg sublingual misoprostol after mifepristone medical abortion through 63 days\u2019 LMP: a randomized controlled trial. Contraception. 2010;82(6):513\u20139.","journal-title":"Contraception"},{"issue":"15","key":"1003_CR32","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1001\/jama.284.15.1948","volume":"284","author":"EA Schaff","year":"2000","unstructured":"Schaff EA, Fielding SL, Westhoff C, Ellertson C, Eisinger SH, Stadalius LS, Fuller L. Vaginal misoprostol administered 1, 2, or 3 days after mifepristone for early medical abortion: a randomized trial. JAMA. 2000;284(15):1948\u201353.","journal-title":"JAMA"},{"issue":"2","key":"1003_CR33","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S0010-7824(01)00229-3","volume":"64","author":"EA Schaff","year":"2001","unstructured":"Schaff EA, Fielding SL, Westhoff C. Randomized trial of oral versus vaginal misoprostol at one day after mifepristone for early medical abortion. Contraception. 2001;64(2):81\u20135.","journal-title":"Contraception"},{"issue":"4","key":"1003_CR34","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S0010-7824(02)00366-9","volume":"66","author":"EA Schaff","year":"2002","unstructured":"Schaff EA, Fielding SL, Westhoff C. Randomized trial of oral versus vaginal misoprostol 2 days after mifepristone 200 mg for abortion up to 63 days of pregnancy. Contraception. 2002;66(4):247\u201350.","journal-title":"Contraception"},{"issue":"6","key":"1003_CR35","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1111\/j.1471-0528.2006.00948.x","volume":"113","author":"C Shannon","year":"2006","unstructured":"Shannon C, Wiebe E, Jacot F, Guilbert E, Dunn S, Sheldon WR, Winikoff B. Regimens of misoprostol with mifepristone for early medical abortion: a randomised trial. BJOG. 2006;113(6):621\u20138.","journal-title":"BJOG"},{"issue":"11","key":"1003_CR36","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1093\/humrep\/deg475","volume":"18","author":"OS Tang","year":"2003","unstructured":"Tang OS, Chan CC, Ng EH, Lee SW, Ho PC. A prospective, randomized, placebo-controlled trial on the use of mifepristone with sublingual or vaginal misoprostol for medical abortions of less than 9 weeks gestation. Hum Reprod (Oxford, Engl). 2003;18(11):2315\u20138.","journal-title":"Hum Reprod (Oxford, Engl)"},{"issue":"5","key":"1003_CR37","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1007\/s00404-015-3722-1","volume":"292","author":"R Tendler","year":"2015","unstructured":"Tendler R, Bornstein J, Kais M, Masri I, Odeh M. Early versus late misoprostol administration after mifepristone for medical abortion. Arch Gynecol Obstet. 2015;292(5):1051\u20134.","journal-title":"Arch Gynecol Obstet"},{"key":"1003_CR38","doi-asserted-by":"crossref","unstructured":"Verma ML, Singh U, Singh N, Sankhwar PL, Qureshi S. Efficacy of concurrent administration of mifepristone and misoprostol for termination of pregnancy. Human fertility (Cambridge, Engl). 2017;20(1):43\u20137.","DOI":"10.1080\/14647273.2016.1243817"},{"issue":"9577","key":"1003_CR39","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/S0140-6736(07)60914-3","volume":"369","author":"H von Hertzen","year":"2007","unstructured":"von Hertzen H, Piaggio G, Huong NT, Arustamyan K, Cabezas E, Gomez M, Khomassuridze A, Shah R, Mittal S, Nair R, Erdenetungalag R, Huong TM, Vy ND, Phuong NT, Tuyet HT, Peregoudov A. Efficacy of two intervals and two routes of administration of misoprostol for termination of early pregnancy: a randomised controlled equivalence trial. Lancet (London, Engl). 2007;369(9577):1938\u201346.","journal-title":"Lancet (London, Engl)"},{"issue":"3","key":"1003_CR40","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/j.1471-0528.2008.02034.x","volume":"116","author":"H Von Hertzen","year":"2009","unstructured":"Von Hertzen H, Piaggio G, Wojdyla D, Marions L, My Huong NT, Tang OS, Fang AH, Wu SC, Kalmar L, Mittal S, Erdenetungalag R, Horga M, Pretnar-Darovec A, Kapamadzija A, Dickson K, Anh ND, Tai NV, Tuyet HT, Peregoudov A. Two mifepristone doses and two intervals of misoprostol administration for termination of early pregnancy: a randomised factorial controlled equivalence trial. BJOG. 2009;116(3):381\u20139.","journal-title":"BJOG"},{"issue":"6","key":"1003_CR41","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1097\/AOG.0b013e31818d8eb4","volume":"112","author":"B Winikoff","year":"2008","unstructured":"Winikoff B, Dzuba IG, Creinin MD, Crowden WA, Goldberg AB, Gonzales J, Howe M, Moskowitz J, Prine L, Shannon CS. Two distinct oral routes of misoprostol in mifepristone medical abortion: a randomized controlled trial. Obstet Gynecol. 2008;112(6):1303\u201310.","journal-title":"Obstet Gynecol"}],"container-title":["BMC Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-020-01003-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12905-020-01003-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-020-01003-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T19:07:35Z","timestamp":1625598455000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcwomenshealth.biomedcentral.com\/articles\/10.1186\/s12905-020-01003-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,7]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1003"],"URL":"https:\/\/doi.org\/10.1186\/s12905-020-01003-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.16633\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.16633\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.16633\/v1","asserted-by":"object"}]},"ISSN":["1472-6874"],"issn-type":[{"value":"1472-6874","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,7]]},"assertion":[{"value":"27 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"142"}}